George Medicines PTY Limited Deal History & Licensing Activity
George Medicines PTY Limited is a biotech. Over the past three years, George Medicines PTY Limited has been involved in 5 licensing and acquisition transactions, with a primary focus on Small Molecules (8 deals).
Deals (12mo)
4
Active Trials
1
Top Modality
Small Molecules
Focus Area
Cardiovascular
George Medicines PTY Limited Recent Deal Activity
Licensing, acquisition, and partnership transactions involving George Medicines PTY Limited in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| GMRx2 | Arrotex Pharmaceuticals | Small Molecules | Phase 3 | license | Mar 16, 2026 |
| GMRx2 | Ahngook Pharmaceutical Co. Ltd | Small Molecules | Phase 3 | license | Mar 11, 2026 |
| GMRx2 | Orient EuroPharma | Small Molecules | Phase 3 | license | Feb 25, 2026 |
George Medicines PTY Limited Pipeline Focus
Therapeutic areas and modalities where George Medicines PTY Limited is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches George Medicines PTY Limited's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Cardiovascular assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About George Medicines PTY Limited Licensing & Deal Activity
George Medicines PTY Limited is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, George Medicines PTY Limited ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for George Medicines PTY Limited include Cardiovascular (8 deals and trials). In terms of modality, George Medicines PTY Limited has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for George Medicines PTY Limited and 700+ other biopharma companies. Use our Solidus to benchmark your asset against George Medicines PTY Limited's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.